WOBURN, Mass., Oct. 18 /PRNewswire/ -- BioTrove, Inc. today announced the appointment of Edward L. Erickson to its board of directors, reflecting BioTrove's increased emphasis on diagnostics and services. Mr. Erickson, current chairman of the board of Immunicon Corporation , expands the BioTrove board to six corporate directors.
"Ed's extensive experience in our industry -- including the successful completion of three IPOs as a CEO and another as an independent director -- will bring added insight to BioTrove as we grow into the medical diagnostics space," said Robert H. Ellis, executive chairman, BioTrove. "His diverse biotech background, which also includes therapeutics and life science research products experience, will help ensure our business strategy is sound and Company goals are met."
Mr. Erickson has served as president, CEO or a director for eight biomedical products companies, including Megabios Corporation, a gene therapy company (director, 1995-1998); DepoTech Corporation, a biopharmaceutical company in the drug delivery field (president and CEO, 1993-1998); Cholestech Corporation, a diagnostics company in point-of-care cholesterol testing and screening (president and CEO, 1991-1993); and most recently, Immunicon Corporation , a company focused on cell- and molecular-based human diagnostic and life science research products and analytical services to pharmaceutical and biotechnology companies (CEO, 1999-2005), where he also served as chairman of the board since 1998. Earlier in his career he held senior management positions with Amersham International and Serono.
Mr. Erickson earned BS and MS degrees from the Illinois Institute of Technology, and an MBA from the Harvard Business School. He did military service as an officer in the U.S. Navy, including duty aboard the U.S.S. Nautilus, the world's first nuclear submarine.
"The perspective afforded by a career as accomplished and diverse as Ed's is an asset to BioTrove," said Albert A. Luderer, Ph.D., president and CEO, BioTrove. "With Ed's addition to the board, our corporate directors now provide access to experience and expertise in each facet of the Company's future development, including our diversification into diagnostic medicine."
Mr. Erickson's fellow BioTrove board members include: * Robert H. Ellis, Chairman. Mr. Ellis leads development efforts for the Company's life science laboratories products and services. His 29 years of analytical and biotechnology instrumentation experience include 17 years in the field of genetic and protein analysis. Most recently, Mr. Ellis was executive vice president responsible for R&D at Affymetrix. * Albert A. Luderer, Ph.D., President and Chief Executive Officer. Dr. Luderer brings to BioTrove 30 years of experience in medical diagnostics, including 17 years in executive positions. Prior to joining BioTrove, Dr. Luderer served for five years as president, CEO and director at Light Sciences, LLC in Seattle, Washington, where he focused on oncology, interventional cardiology, and ophthalmologic diseases and successfully coordinated the spin-off of Light Sciences Oncology. * Colin Brenan, Ph.D., Chief Technology Officer, SVP, Research and Engineering Development, and Co-founder of BioTrove. Dr. Brenan is the co-founder of four early-stage ventures including, most recently, BioTrove, Inc. His experience in scientific research, technical program management, and product development spans more than 21 years, including work with Professor Ian Hunter at the Massachusetts Institute of Technology to create novel nano- and micro-scale biomedical instrumentation. He holds six patents in communications, microfluidic systems, and optical technologies. * Joshua Phillips, Managing Director, Catalyst Health & Technology Partners. Mr. Phillips' investment interests at Catalyst span both the life sciences and technology markets, with particular interest in drug discovery tools and enterprise software. His experience with building businesses includes work in venture capital, strategy consulting, management, and engineering. * Enrico Petrillo, M.D., General Partner of CB Health Ventures, LLC. Dr. Enrico Petrillo is a General Partner of CB Health Ventures, LLC. His consulting experience includes clients in the pharmaceutical, information technology, biotechnology and medical device industries, as well as venture capital and private equity firms. He acted as a key advisor for new technology ventures with major research centers including Harvard Medical School, Massachusetts Institute of Technology, Children's Hospital Medical Center (Boston), and Dana Farber Cancer Institute. About BioTrove, Inc.
BioTrove offers two innovative platform technologies, dramatically increasing pharmaceutical screening and SNP genotyping throughput for the purpose of accelerating drug-discovery decisions and pipeline development. Its products and services ensure that an industry committed to accuracy and speed can meet business goals.
RapidFire(TM) Lead Discovery enables difficult targets (lipids, fatty acids, phospholipids, steroids, prostaglandins, and others) to be screened using high throughput mass spectrometry in less than eight seconds per sample.
OpenArray(TM) enables genomics researchers to generate SNP data in the hundreds of thousands of data points. The flexible format and nanoliter scale of the OpenArray(TM) system allows for easy adjustment of sample and assay numbers, achieving economical, high-throughput genotyping.
For more information, please visit http://www.biotrove.com or contact: Dr. Albert A. Luderer, President and CEO BioTrove, Inc. 781-721-3648 aluderer@biotrove.com Arielle Bernstein Makovsky + Company 212-508-9643 abernstein@makovsky.com
BioTrove, Inc.CONTACT: Dr. Albert A. Luderer, President and CEO, BioTrove, Inc.,+1-781-721-3648, aluderer@biotrove.com; or Arielle Bernstein, Makovsky +Company, +1-212-508-9643, abernstein@makovsky.com
Web site: http://www.biotrove.com/
